An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis
{{output}}
Introduction: Risankizumab (RZB) is a recombinant IgG1 humanized monoclonal antibody which selectively inhibits interleukin (IL)-23 though high-affinity binding of the p19 subunit. RZB was approved for use in Crohn's disease (CD)... ...
